CN113661176B - 用于预防和治疗单纯疱疹病毒感染的单克隆抗体 - Google Patents

用于预防和治疗单纯疱疹病毒感染的单克隆抗体 Download PDF

Info

Publication number
CN113661176B
CN113661176B CN202080021839.7A CN202080021839A CN113661176B CN 113661176 B CN113661176 B CN 113661176B CN 202080021839 A CN202080021839 A CN 202080021839A CN 113661176 B CN113661176 B CN 113661176B
Authority
CN
China
Prior art keywords
seq
ser
thr
antibody
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080021839.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113661176A (zh
Inventor
贝琪·C·赫罗尔德
加尼特·凯尔索
仓冈雅征
克莱尔·伯恩
威廉·R·小雅各布斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Duke University
Original Assignee
Albert Einstein College of Medicine
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine, Duke University filed Critical Albert Einstein College of Medicine
Priority to CN202510126123.8A priority Critical patent/CN119899260A/zh
Publication of CN113661176A publication Critical patent/CN113661176A/zh
Application granted granted Critical
Publication of CN113661176B publication Critical patent/CN113661176B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080021839.7A 2019-03-19 2020-03-19 用于预防和治疗单纯疱疹病毒感染的单克隆抗体 Active CN113661176B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510126123.8A CN119899260A (zh) 2019-03-19 2020-03-19 用于预防和治疗单纯疱疹病毒感染的单克隆抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820495P 2019-03-19 2019-03-19
US62/820,495 2019-03-19
PCT/US2020/023600 WO2020191181A1 (en) 2019-03-19 2020-03-19 Monoclonal antibodies for prevention and treatment of herpes simplex viral infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510126123.8A Division CN119899260A (zh) 2019-03-19 2020-03-19 用于预防和治疗单纯疱疹病毒感染的单克隆抗体

Publications (2)

Publication Number Publication Date
CN113661176A CN113661176A (zh) 2021-11-16
CN113661176B true CN113661176B (zh) 2025-02-18

Family

ID=70285944

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080021839.7A Active CN113661176B (zh) 2019-03-19 2020-03-19 用于预防和治疗单纯疱疹病毒感染的单克隆抗体
CN202510126123.8A Pending CN119899260A (zh) 2019-03-19 2020-03-19 用于预防和治疗单纯疱疹病毒感染的单克隆抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510126123.8A Pending CN119899260A (zh) 2019-03-19 2020-03-19 用于预防和治疗单纯疱疹病毒感染的单克隆抗体

Country Status (9)

Country Link
US (1) US12459987B2 (enExample)
EP (1) EP3941524A1 (enExample)
JP (1) JP7835392B2 (enExample)
KR (1) KR20210141948A (enExample)
CN (2) CN113661176B (enExample)
AU (1) AU2020242042A1 (enExample)
CA (1) CA3133862A1 (enExample)
IL (1) IL286415A (enExample)
WO (1) WO2020191181A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805579B (zh) * 2022-06-08 2023-06-06 郑州大学 一种抗人ace2蛋白单克隆抗体、核酸分子及应用
TWI876557B (zh) * 2022-09-30 2025-03-11 臺北醫學大學 用於前列腺癌診斷和早期發病的單株抗體
CN119751660B (zh) * 2024-12-02 2026-04-03 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种猫麻疹病毒特异性单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156313A (en) * 1994-01-04 2000-12-05 The Scripps Research Institute Human monoclonal antibodies to herpes simplex virus and methods therefor
CN106488931A (zh) * 2014-06-26 2017-03-08 海德堡免疫疗法有限公司 抗hsv抗体的局部应用
WO2019044926A1 (ja) * 2017-08-30 2019-03-07 Ｋｍバイオロジクス株式会社 抗ＨＳＶ ｇＢモノクローナル抗体又はその抗原結合断片

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
EP2308895A1 (en) * 2009-10-01 2011-04-13 Universität Duisburg-Essen Anti-HSV antibody
JP2020504105A (ja) 2016-12-19 2020-02-06 グレンマーク・ファーマシューティカルズ・エスエー 新規なｔｎｆｒアゴニストおよびその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156313A (en) * 1994-01-04 2000-12-05 The Scripps Research Institute Human monoclonal antibodies to herpes simplex virus and methods therefor
CN106488931A (zh) * 2014-06-26 2017-03-08 海德堡免疫疗法有限公司 抗hsv抗体的局部应用
WO2019044926A1 (ja) * 2017-08-30 2019-03-07 Ｋｍバイオロジクス株式会社 抗ＨＳＶ ｇＢモノクローナル抗体又はその抗原結合断片

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacity;Martin P. Da¨umer et al;Med Microbiol Immunol;第200卷(第2期);第89页左栏Results，第91页表2，第93页图4以及第95页第4段 *

Also Published As

Publication number Publication date
WO2020191181A9 (en) 2020-12-10
US12459987B2 (en) 2025-11-04
CN113661176A (zh) 2021-11-16
JP7835392B2 (ja) 2026-03-25
KR20210141948A (ko) 2021-11-23
AU2020242042A1 (en) 2021-09-16
IL286415A (en) 2021-10-31
CA3133862A1 (en) 2020-09-24
JP2022525535A (ja) 2022-05-17
CN119899260A (zh) 2025-04-29
EP3941524A1 (en) 2022-01-26
WO2020191181A1 (en) 2020-09-24
US20220162291A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
JP6783886B2 (ja) 抗ｃｔｌａ４モノクローナル抗体またはその抗原結合断片、医薬組成物および使用
US20250034248A1 (en) Monoclonal antibodies against human tim-3
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
SG11202108281UA (en) Claudin 6 antibodies and uses thereof
US20250223353A1 (en) Anti-pvrig antibody, pharmaceutical composition thereof and use thereof
JP2023542209A (ja) ヒトｃｄ３イプシロンに結合する新規なヒト抗体
KR20170110681A (ko) Pcsk9 항체, 및 약제학적 조성물 및 이의 용도
AU2021372706A1 (en) Anti-tigit antibody, and pharmaceutical composition and use thereof
US12459987B2 (en) Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
US20240002500A1 (en) Anti-TIGIT Antibody or Antigen-Binding Fragment Thereof
CN114075283A (zh) 结合人cd38的抗体、其制备方法和用途
WO2019200255A1 (en) High-affinity mycobacterium tuberculosis capsule-specific human monoclonal antibody
WO2022127066A9 (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
CN114437215B (zh) 抗人cd38抗体及其制备方法和用途
RU2777336C1 (ru) Моноклональные антитела к tim-3 человека
WO2026041144A1 (zh) Pd-1激动性抗体及其用途
EA049283B1 (ru) Антитело к tigit и его фармацевтическая композиция и применение
US20210163578A1 (en) High-affinity mycobacterium tuberculosis capsule-specific human monoclonal antibody
AU2023370497A1 (en) Antibodies against cd24 and uses thereof
CN119285768A (zh) Tigit抗体及其应用
HK40043135B (zh) 针对人tim-3的单克隆抗体
HK40043135A (en) Monoclonal antibodies against human tim-3
CN121319169A (zh) 抗相思子毒素中和抗体、其药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant